The Renin-Angiotensin System in Essential Hypertension

Status

Terminated

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00141583

Enrollment

Registered

2005-09-01

Start date

2004-04-30

Completion date

2006-10-31

Last updated

2015-06-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension

Keywords

Renin-angiotensin system, ACE Inhibitor, Angiotensin Receptor Blocker

Brief summary

Although ACE Inhibitors and Angiotensin Receptor Blockers are effective blood pressure lowering agents, the exact mechanisms by which these agents lower BP are still not fully understood. This study aims to compare the blood pressure and hormonal responses (plasma renin activity and aldosterone) to the ACE inhibitor enalapril and ARB candesartan in individuals with mild essential hypertension.

Interventions

DRUGEnalapril 20 mg bd

DRUGCandesartan 8 mg bd

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 70 Years

Healthy volunteers

Inclusion criteria

* Essential Hypertension * SBP 140-159 mmHg * DBP 90-99 mmHg

Exclusion criteria

* Intolerance of or allergy to ACE Inhibitors or ARBS * Pregnant or Breastfeeding * Pre-menopausal women * Uncontrolled cardiac or renal failure * Diabetes mellitus

Design outcomes

Primary

Measure	Time frame
Change in BP	—
Change in PRA and aldosterone	—

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026